


## CLAIMS

1. A compound selected from the group consisting of the azole derivatives having the general formula




including the salts thereof with pharmaceutically acceptable acids, the N-oxide forms thereof and the stereochemical isomers thereof, where:

A is N or CH;

Het is an aromatic heterocyclic radical containing one or more O, N or S atoms, optionally substituted with one or more 5- or 6-membered aromatic rings;

B is an alcanoic residue containing from 1 to 6 carbon atoms or is a residue of the formula



where:


R1 is hydrogen or a linear or branched alkyl residue containing from 1 to 6 carbon atoms and optionally substituted in one or more positions by hydroxyl groups;

R2 and R3, taken separately, are hydrogen or an alkyl with 1-4 carbon atoms or, taken together, are a divalent radical of the formula -CH=N-, -N=CH-, -CH=CH-, -CH2-CH2-.

2. A compound according to claim 1 in which A) is a nitrogen atom.
3. A compound according to any one of the preceding claims in which Het is selected from among: pyridine, pyridazine, pyrazine, pyrimidine, thiophene, oxazole, thiazole, pyrrole, pyrazole, imidazole, triazole and


any corresponding fusion derivatives having two or more rings or with one or more benzene rings.

4. A compound according to any one of the preceding claims in which B) is formyl, acetyl or propanoyl.
5. A compound according to any one of the preceding claims in which B has the formula:




where R1 is hydrogen or a linear or branched alkyl residue containing from 1 to 6 carbon atoms and optionally substituted in one or more positions by hydroxyl groups.


6. A compound selected from the group consisting of *cis*-4-[4-[4-[2-(2-pyridinyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-1-piperazinyl]-phenyl]-2-(1-methyl)-propyl-2,4-dihydro-3H-1,2,4-triazol-3-one, the salts thereof with pharmaceutically acceptable acids and the stereochemical isomers thereof.
7. A compound according to claims 1-6 for use as a medicament.
8. Use of a compound according to claims 1-6 for the production of a pharmaceutical formulation for treating fungal and bacterial infections.
9. Use according to claim 8 for treating infections by *Candida albicans*, *Candida glabrata*, *Candida parapsilosis*, *Aspergillus fumigatus*.
10. A pharmaceutical composition containing a compound according to claims 1-6, alone or in combination with at least one other active ingredient, together with one or more pharmaceutically acceptable excipients and/or auxiliary substances.
11. A process for the production of a compound according to claims 1-6 in which a compound of the formula III

Formula (III)

where: A is N or CH and Het is an aromatic heterocyclic radical containing one or more O, N or S atoms, optionally substituted with one or more 5- or 6-membered aromatic rings;  
is reacted with a compound of the formula

Formula (IV)

where: B is an alkanoic residue containing from 1 to 6 carbon atoms or is a residue of the formula



where: R1 is hydrogen or a linear or branched alkyl residue containing from 1 to 6 carbon atoms and optionally substituted in one or more positions by hydroxyl groups; R2 and R3, taken separately, are hydrogen or an alkyl with 1-4 carbon atoms or, taken together, are a divalent radical of the formula -CH=N-, -N=CH-, -CH=CH-, -CH<sub>2</sub>-CH<sub>2</sub>-.